CPIM
VRTX icon

Columbia Partners Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Columbia Partners Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,354
Closed -$1.16M – 344
2013
Q3 		$1.16M Buy
+15,354
New +$1.22M 0.05% 235

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Columbia Partners Investment Management's VRTX Position: Q4 2013 in Review

Columbia Partners Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2013, closing a stake of 15,354 shares — an estimated $1.16M sold.

Columbia Partners Investment Management first reported a position in VRTX in Q3 2013 and held it in 1 quarter. The position peaked at $1.16M in Q3 2013. 387 funds tracked by Wall St. Rank hold VRTX as of Q4 2013.

  • Columbia Partners Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Columbia Partners Investment Management sold 15,354 Vertex Pharmaceuticals shares in Q4 2013, an estimated $1.16M.
  • Columbia Partners Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Columbia Partners Investment Management's Vertex Pharmaceuticals position peaked at $1.16M in Q3 2013.
  • 387 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2013.

Based on Columbia Partners Investment Management's 13F filing for Q4 2013, filed 11 Feb 2014.